Price of hepatitis C drug attacked - Financial Times

[INCIID News Feed]

Drug Discovery & Development
<img alt="" height="1" width="1" />
Price of hepatitis C drug attacked
Financial Times
Gilead Sciences is facing mounting pressure over its new $1,000-a-day hepatitis C drug after the World Health Organisation joined US politicians and healthcare companies in voicing concerns over the price. Sovaldi is on course to become the most ...
WHO Seeks to Lower the Price of New Hepatitis C Drug, SovaldiScience World Report
Will New Hepatitis C Guidelines From WHO Help Make Sovaldi And Other New ...Medical Daily
WHO Wants New Hepatitis C Drug Accessible to AllNews on Wellness
CBS Local -Reuters
all 87 news articles &raquo;


More...